Applying Brave
Science to
Diseases
and Conditions
We have an FDA-approved treatment for tardive dyskinesia and Huntington’s disease chorea, as well as a robust pipeline including multiple compounds in mid-to-late phase clinical development across our core therapeutic areas.
While others walk away
from complex disease
states, our team
persists
Neurocrine Biosciences is fully
invested in bringing medicines
to market for people with under-
addressed and rare diseases.
References
1. University of Michigan Health. Movement disorders. Accessed July 12, 2022. https://www.uofmhealth.org/conditions-treatments/brain-neurological-conditions/movement-disorders
2. MedlinePlus. Movement disorders. Accessed July 12, 2022. https://medlineplus.gov/movementdisorders.html
3. Epilepsy Foundation. Who can get epilepsy? Accessed July 12, 2022. https://www.epilepsy.com/learn/about-epilepsy-basics/who-gets-epilepsy
4. National Organization for Rare Disorders. Congenital adrenal hyperplasia. Accessed July 12, 2022. https://rarediseases.org/rare-diseases/congenital-adrenal-hyperplasia/
5. Our World in Data. Mental health. Accessed July 12, 2022. https://ourworldindata.org/mental-health
6. National Library of Medicine. MedlinePlus. Uterine fibroids. Accessed July 12, 2022. https://medlineplus.gov/uterinefibroids.html
7. National Library of Medicine. MedlinePlus. Endometriosis. Accessed July 12, 2022. https://medlineplus.gov/endometriosis.html